South Africa to Spend $2.2 billion on HIV Drugs in Next 2 Years

South Africa plans to spend $2.2 billion over two years to buy HIV/AIDS drugs for public hospitals, a government minister said on Monday, as a study shows the prevalence of the virus is rising

Join Our Community of Science Lovers!

PORT ELIZABETH South Africa (Reuters) - South Africa plans to spend $2.2 billion over two years to buy HIV/AIDS drugs for public hospitals, a government minister said on Monday, as a study shows the prevalence of the virus is rising.

Speaking at a manufacturing plant of drugmaker Aspen Pharmacare, Trade and Industry Minister Rob Davies said the government aims to buy three quarters of the drugs from local manufacturers.

"We are on the cusp of a very important tender worth 24 billion rand ($2.2 billion) by the Department of Health that is for the procurement of anti-retrovirals for 2015," Davies told reporters at Aspen's factory in the coastal city of Port Elizabeth.

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

South Africa awarded a $667 million two-year contract in 2012 to pharmaceutical firms including the country's biggest, Aspen, and U.S.-based Abbott Laboratories.

Aspen, which won more about a third of that contract, would also be bidding this year and its chief executive Stephen Saad said his company was aiming for more than a 50 percent share.

South Africa has one of the world's heaviest HIV/AIDS case loads and its biggest treatment program. But despite government efforts to spread the treatment, medical charities warned last year that many clinics were running out of the life-saving drugs.

(Reporting by Tiisetso Motsoenen; Editing by David Dolan and Michael Urquhart)

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American